Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 13, 2025
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial -
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025 -
Read more at globenewswire.comNASDAQ:DWTX (10/27/2025, 1:29:01 PM)
5.96
+0.08 (+1.36%)
Find more stocks in the Stock Screener
